Title:
CANCER TREATMENT DRUG
Document Type and Number:
WIPO Patent Application WO/2019/050036
Kind Code:
A1
Abstract:
The present invention provides: a peptide that includes a partial amino acid sequence of the C16orf74 protein, includes the cysteine at position 7 and/or the cysteine at position 14 of the C16orf74 protein, and inhibits dimer formation of the C16orf74 protein; a pharmaceutical composition for cancer treatment that includes the peptide; and a screening method for cancer treatment drugs that takes as the indicator inhibition of dimer formation of the C16orf74 protein.
Inventors:
NAKAMURA TORU (JP)
Application Number:
PCT/JP2018/033502
Publication Date:
March 14, 2019
Filing Date:
September 10, 2018
Export Citation:
Assignee:
UNIV HOKKAIDO NAT UNIV CORP (JP)
International Classes:
C12N15/12; A61K35/76; A61K38/17; A61K45/00; A61K48/00; A61P1/18; A61P35/00; A61P43/00; C07K7/08; C07K14/47; C07K19/00; C12Q1/02; G01N33/15; G01N33/50
Foreign References:
| JP2006500947A | 2006-01-12 | |||
| JP2009502735A | 2009-01-29 |
Other References:
FUTAKI, SHIROH ET AL.: "Arginine-rich Peptides", J. BIOL. CHEM., vol. 276, no. 8, 2001, pages 5836 - 5840, XP002210171, DOI: doi:10.1074/jbc.M007540200
NAKAMURA, TORU ET AL.: "Overexpression of C16orf74 is involved in aggressive pancreatic cancers", ONCOTARGET, vol. 8, no. 31, 28 July 2016 (2016-07-28), pages 50460 - 50475, XP055581402, DOI: 10.18632/oncotarget.10912
TAN, MING ET AL.: "Selective Inhibition of ErbB2- Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3-Blocking Peptide", CANCER RES., vol. 66, no. 7, 1 April 2006 (2006-04-01), pages 3764 - 3772, XP055581407, DOI: 10.1158/0008-5472.CAN-05-2747
SATO, SHOKI ET AL.: "Molecular targeting of cell - permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation", ONCOTARGET, vol. 8, no. 69, 19 October 2017 (2017-10-19), pages 113662 - 113672, XP055581412, DOI: 10.18632/oncotarget.21939
NAKAMURA T ET AL., ONCOTARGET, 28 July 2016 (2016-07-28)
NAKAMURA, TORU ET AL.: "Overexpression of C16orf74 is involved in aggressive pancreatic cancers", ONCOTARGET, vol. 8, no. 31, 28 July 2016 (2016-07-28), pages 50460 - 50475, XP055581402, DOI: 10.18632/oncotarget.10912
TAN, MING ET AL.: "Selective Inhibition of ErbB2- Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3-Blocking Peptide", CANCER RES., vol. 66, no. 7, 1 April 2006 (2006-04-01), pages 3764 - 3772, XP055581407, DOI: 10.1158/0008-5472.CAN-05-2747
SATO, SHOKI ET AL.: "Molecular targeting of cell - permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation", ONCOTARGET, vol. 8, no. 69, 19 October 2017 (2017-10-19), pages 113662 - 113672, XP055581412, DOI: 10.18632/oncotarget.21939
NAKAMURA T ET AL., ONCOTARGET, 28 July 2016 (2016-07-28)
Attorney, Agent or Firm:
YAMAO, Norihito et al. (JP)
Download PDF: